HMGB1 and colorectal cancer: A number of studies have indicated that HMGB1 overexpression is associated with a worse prognosis in patients with several inflammation-associated cancers, such as hepatocellular carcinoma [35–37], colorectal cancer [38, 39], and cervical carcinoma [40, 41].